

Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GNANLEX

Nitazoxanide

A. Active patents

S.no.	Title	Assignee	Patent details	Type of patent	Remarks
1.	Viral Hepatitis Treatment	Romark Laboratories, L.C.	App no/Grant no: IN264839 (4143/CHENP/2008) Priority Date/Filing date: 09/01/2006 06/08/2008 Grant date: 23/01/2015 Expected expiry date: 09/01/2027 Form 27: Not worked	Nitazoxanide + interferon formulation	No Patent Barrier
2.	Controlled Release Pharmaceutical Formulations of Nitazoxanide	Romark Laboratories L.C.	App no/Grant no: IN298233 (6860/DELNP/2011) Priority Date/Filing date: 13/02/2009 08/06/2011 Grant date: 28/06/2018 Expected expiry date: 12/02/2023 Form 27: not yet worked in India	CR formulation of nitazoxanide	Patent Barrier. However, can be worked around

B. Pending applications

S.no.	Title	Assignee	Application details	Type of patent	Remarks
1.	Therapeutic Agent for Phosphodiesterase Inhibition and its Related Disorders.	Novalead Pharma Inc.	App No: 201721009758 Filing Date: 23/03/2017 Published Date: 12/07/2019 Status: Application Published	Nitazoxanide formulation	Currently, no patent barrier. Can be work around.

C. Expired/Lapsed applications

S.no.	Title	Assignee	Application details	Type of patent	Remarks
1.	Pharmaceutical Composition Comprising Nitazoxanide	RA Chem Pharma Limited	App No: 783/CHE/2010 Filing Date:	Sustained release formulation of	No patent barrier.

Commissioned by



Task Force on Repurposing of Drugs (TFORD) for COVID-19**Patent status in India: by GNANLEX**

			24/03/2010 Published Date: 06/07/2012 Status: Application Published	Nitazoxanide	
--	--	--	---	--------------	--

Disclaimer:

Search results are up to 21st May 2020

GNANLex's Opinion / Report as hereinabove is to the best of our knowledge, true and accurate as of the date compiled based on available information. However, no guarantee is made as to its accuracy, reliability or completeness. The final user is expected to assume sole liability for any patent infringement that occurs by following our recommendations or using the information given. Before using, user should determine the suitability of the information for his intended use. The risk and liability, if any, in connection therewith, is solely that of the user.

Commissioned by